Werfen to acquire Omixon expanding its portfolio in transplant diagnostics


Werfen to acquire Omixon expanding its portfolio in transplant diagnostics


  • Werfen expects to acquire Omixon, a privately held corporation headquartered in Budapest, Hungary, focused on the development and commercialization of Next Generation Sequencing (NGS) technologies in transplant diagnostics.
  • The transaction is expected to be completed during 2024 subject to customary closing conditions.


Barcelona, Spain May 15, 2024.- Werfen announced today that it has agreed to acquire Omixon, a privately held corporation with an innovative portfolio in transplant diagnostics headquartered in Budapest, Hungary. The acquisition will allow Werfen to expand its portfolio of transplant diagnostics solutions for hospitals and clinical laboratories.

The purchase price is expected to be approximately US$25 million and will be funded with cash on hand. The acquisition is subject to customary closing conditions.

“One year after the acquisition of Immucor, this announcement reinforces our commitment to continue investing in transplant diagnostics” said Carlos Pascual, Werfen CEO.

Pascual continued, “Omixon is a perfect fit to expand our transplant business line with a comprehensive NGS portfolio, coupled with strong bioinformatics capabilities and an exciting pipeline of new solutions.”

“This transaction is not expected to impact our fast-deleveraging trend and our solid commitment to the investment grade rating” said Javier Gómez, Werfen CFO. “Following our prudent financial policy, we are on track to achieve our objective of reducing the financial leverage ratio below 3.0x between the end of the current year and the first quarter of 2025.”

“We are thrilled to join forces with Werfen renowned for its excellence in specialized diagnostics,” said Attila Bérces, PhD, Founder and CEO of Omixon. “This partnership presents an exciting opportunity to leverage our respective strengths and resources to further advance transplant diagnostics and make a meaningful impact in the field of transplantation worldwide.”


Founded in 1966, Werfen is a developer, manufacturer, and worldwide distributor of specialized diagnostic instruments, related reagents, automation work cells, and data management solutions for use primarily in hospitals and independent clinical laboratories. The company’s business lines include Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity, Transplant, and Original Equipment Manufacturing (OEM). Werfen operates directly in more than 30 countries and more than 100 territories through distributors. For more information, visit werfen.com


Omixon is a global transplantation diagnostic company with a mission to provide histocompatibility laboratories with innovative technologies to improve transplant outcomes. Omixon is headquartered in Budapest, Hungary, with operations in the United States, Brazil and the Netherlands serving more than 60 laboratories worldwide.

Building on multidisciplinary competencies in bioinformatics, software engineering, molecular biology, and regulatory science, Omixon transforms molecular biology innovations.

Legal notice

This document contains forward-looking statements about our business, financial data, and events related to the prospects of Werfen. These forecasts can be identified by the use of words such as “expectation”, “vision”, “anticipation”, “intention”, “plan”, “belief”, “search”, “estimate”, “future”, “project”, or words with a similar meaning. We may also make projections in other reports, presentations, and press releases. Furthermore, our sales representatives may occasionally make forward-looking statements. These projections are based on our current expectations and on certain hypotheses, many of which are beyond the corporation’s control and subject to a series of risks and uncertainties. In the event that any of these risks or uncertainties should materialize or the underlying expectations are not fulfilled, the results or performance of Werfen may differ substantially (either positively or negatively) from those explicitly or implicitly forecast. Werfen assumes no obligation to update or revise any forward-looking statements made previously.